BORTEZOMIB JUNO, BORTEZOMIB JN (Juno Pharmaceuticals Pty Ltd)

BORTEZOMIB JUNO, BORTEZOMIB JN (powder for injection) is indicated for:

• in combination with melphalan and prednisone, the treatment of patients with previously untreated multiple myeloma who are not candidates for high dose chemotherapy;
• as part of combination therapy, for induction therapy prior to high dose chemotherapy with autologous stem cell rescue for patients under 65 years of age with previously untreated multiple myeloma;
• the treatment of multiple myeloma patients who have received at least one prior therapy, and who have progressive disease; and
• in combination with rituximab, cyclophosphamide, doxorubicin and prednisone, for the treatment of adult patients with previously untreated mantle cell lymphoma.